Symptom-Based Progression-Free Survival (S-PFS) as a Clinically Relevant and Patient-Centric Endpoint in Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Results From the ALPINE Trial

Using data from the ALPINE trial, this analysis demonstrates that worsening patient-reported symptoms, particularly fatigue, insomnia, and nausea/vomiting, is significantly associated with increased risk of disease progression in patients with relapsed/refractory CLL/SLL. Zanubrutinib was associated with a lower probability of symptom deterioration and improved progression-free survival compared with ibrutinib, supporting symptom-based PFS (s-PFS) as a clinically meaningful, patient-centric endpoint for future CLL trials.